Abstrakt

In recent years a multimodal management strategy in the treatment of locally advanced Barrett’s carcinoma has been established. Basically, the multimodal management of esophageal carcinomas of different etiology is currently similar, although there are differences in therapy effectiveness among the various entities of esophageal carcinoma. Principle by neoadjuvant treatment with radiochemotherapy higher R0 resection rate is achieved, which is crucial for improved prognosis. Possible molecular markers that predict a response to neoadjuvant therapy may have been found in Barrett’s cancer already, however currently prospective studies for validation of individual markers, such as ERCC1, an already in other tumors described predictive marker, are lacking.

Autoreninformation

Autoren

• P.P. Grimminger
• A.H. Hölscher

Abteilungen

• Klinik und Poliklinik für Allgemein-, Viszeral- und Tumorchirurgie, Universitätsklinikum Köln

Adresse

Prof. Dr. med. A.H. Hölscher
Klinik und Poliklinik für Allgemein-, Viszeral- und Tumorchirurgie
Universitätsklinikum Köln
Kerpener Straße 62
D–50937 Köln
Email: [email protected]

Citation